Abstract
The dose-effect of oxotremorine upon the onset, duration and magnitude of tremor and salivation was studied in both mice and rats. The threshold doses of oxotremorine (SC) for eliciting tremor were above 50 μg/kg in mice and above 150 μg/kg in rats and the threshold doses for eliciting salivation were above 75 μg/kg in mice and above 200 μg/kg in rats. Alaproclate, a nontricyclic 5-HT uptake inhibitor, when injected 30 min prior to the administration of the cholinergic agonist, produced a dose-dependent enhancement of tremor and salivation in both rats and mice. Alaproclate itself did not produce these effects in the absence of a muscarinic cholinergic stimulant such as oxotremorine, arecoline or the acetylcholine esterase inhibitor physostigmine. Both salivation and tremor could be fully blocked by atropine at any dose of the cholinergic stimulant and of alaproclate used. The potentiating effects of alaproclate on salivation and tremor could also be blocked by two serotonin receptor antagonists, metitepine and danitracen, but not by metergoline or cinanserin. Other compounds which inhibit the uptake of 5-HT such as fluoxetine, citalopram, norzimeldine, zimeldine and the non-tricyclic antidepressant, iprindol, did not enhance the cholinergic agonist induced tremor or salivation under the same conditions as did alaproclate. It is suggested that alaproclate exerts the potentiating effect at a hitherto undefined serotonergic receptor site.
Similar content being viewed by others
References
Babkin BP (1950) Secretory mechanisms of the digestive glands. 2nd Ed., Hoeber, New York
Baker WW, Lalley PM, Connor JD, Rosse GV (1976) Neuropharmacologic analysis of cholinergic tremor mechanisms in the caudate nucleus. Pharmacol Ther C. 1 pp 459–473
Bartholini G, Stadler H, Lloyd KG (1975) Cholinergic-dopaminergic interactions in neuroendocrine regulation. In: Waser PG (ed) Cholinergic Mechanisms. Raven Press, New York, p 411
Bartus RT, Dean RL III, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417
Connor JD, Rossi GV, Baker WW (1966) Analysis of the tremor induced by injection of cholinergic agents into the caudate nucleus. Int J Neuropharmacol 5:207–216
Greengrass P, Bremner R (1979) Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors. Eur J Pharmacol 55:323–326
Hall H, Ögren SO (1981) Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 70:393–407
Herman ZS, Slominska-Zurek J (1979) Central cholinergic receptor supersensitivity after long-term atropine administration. Psychopharmacology 64:337–340
Hyttel J (1982) Citalopram—pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol Biol Psychiatry 6:277–295
Inch TD, Green DM, Thompson PBJ (1973) The central and peripheral activities of anti-acetylcholine drugs. Some concepts of practical relevance. J Pharm Pharmacol 25:359–370
Jones BE, Guyenet P, Cheramy A, Gauchy C, Glowinski J (1973) The in vivo release of acetylcholine from cat caudate nucleus after pharmacological and surgical manipulations of dopaminergic nigrostriatal neurons. Brain Res 64:355–369
Karczmar AG (1977) Exploitable aspects of central cholinergic functions, particularly with respect to the EEG, motor, analgesic and mental functions. In: Jenden DJ (ed) Cholinergic mechanisms and psychopharmacology, Vol 24: Advances in behavioural biology. Plenum Press, New York, p 679
Katsuragi T, Furukawa T (1979) Methysergide induces selective potentiation in cholinergic contractions of the guinea-pig vas deferens by facilitating acetylcholine release. J Pharm Pharmacol 31:822–825
Ladinsky H, Consolo S, Peri G, Crunelli V, Samanin R (1977) Pharmacological evidence for a serotoninergic-cholinergic link in the striatum. In: Jenden DJ (ed) Cholinergic mechanisms and psychopharmacology, Vol 24: Advances in behavioural biology. Plenum Press, New York, p 615
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R41468, a novel antagonist at 5-HT2 receptors. Life Sci 28:1015–1022
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) 3H-ketanserin (R41468), a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314
Maayani S, Egozi Y, Pinchasi I, Sokolovsky M (1977) On the interactions of drugs with the cholinergic nervous system—IV. Biochem Pharmacol 26:1681–1687
Maj J, Baran L, Sowinska H, Gancarczyk L (1976) Central action of WA-335. Arch Immunol Ther Exp 24:205–227
Martin LL, Sanders-Bush E (1982) Comparison of the pharmacological characteristics of 5-HT1 and 5-HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn-Schmiedeberg's Arch Pharmacol 321:165–170
Menkes DB, Baraban JM, Aghajanian GK (1981) Prazosin selectively antagonises neuronal responses mediated by 264-1 in brain. Naunyn-Schmiedeberg's Arch Pharmacol 317:273–275
Ögren SO, Berge O-G (1985) Evidence for selective serotonergic receptor involvement in p-chloroamphetamine-induced antinociception. Naunyn-Schmiedeberg's Arch Pharmacol (in press)
Ögren SO, Holm A-C, Hall H, Lindberg U (1984) Alaproclate, a new selective 5-HT uptake inhibitor with therapeutic potential in depression and senile dementia. J Neural Transm 59:265–288
Ögren SO, Nordström Ö, Danielsson E, Peterson L-O, Bartfai T (1985) In vivo and in vitro studies on the potentiation of muscarinic receptor stimulation by alaproclate, a selective 5-HT uptake blocker. J Neural Transm 61:1–20
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: Differential binding of (3H)-5-hydroxytryptamine, (3H)-lysergic acid diethylamide and (3H)-spiroperidole. Mol Pharmacol 16:687–699
Rossor MN (1982) Neurotransmitters and CNS disease. Dementia. Lancet 27:1200–1204
Siegel S (1956) Nonparametric statistics for the behavioural sciences. Hill Book, New York
Silbergeld EK, Hruska RE (1979) Tremor: role of striatal cholinergic neurons and the effect of intrastriatal kainic acid. Neurosci Lett 15:235–242
Snyder SH, Yamamura HI (1977) Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 34:236–239
Taylor P (1980) Cholinergic agonists. In: Goodman Gilman A, Goodman LS, Gilman A (eds) Goodman and Gilman's The pharmacological basis of therapeutics, 6th Ed, MacMillan, New York, p 91
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ogren, S.O., Carlsson, S. & Bartfai, T. Serotonergic potentiation of muscarinic agonist evoked tremor and salivation in rat and mouse. Psychopharmacology 86, 258–264 (1985). https://doi.org/10.1007/BF00432210
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00432210